Gout Therapeutics Market: Rapidly Evolving Industry…… COVID-19….


The global gout therapeutics market is expected to reach a value of USD 8.3 billion By 2025, based on a new report by Grand View Research, Inc. The gout therapeutics market is anticipated to witness significant growth during the forecast period. This can be attributed to the introduction of major urate-lowering agents, approval of effective biologics, and increasing number of patients suffering from chronic gout.
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
In December 2015, AstraZeneca’s product, Zurampic (lesinurad), in combination with xanthine oxidase inhibitor (XOI) received an approval from the U. S. FDA to treat gout. Later in February 2016, the European Commission approved the drug throughout the European Union (EU). Hence, introduction of urate-lowering agents is expected to drive the market.
Introduction of biologics to treat gout and increasing adoption of newer therapies further help propel the industry. For instance, in March 2013, Novartis received an EU approval for the product, Ilaris, for use in the treatment of patients suffering from gouty arthritis.
Some of the key players in the industry include GlaxoSmithKline plc; Savient Pharmaceuticals; Takeda Pharmaceutical Company Ltd.; Novartis AG; AstraZeneca plc; Merck & Co. Inc.; Teijin Pharma Ltd.; and Regeneron Pharmaceuticals.
To Request Sample Copy of this report, click the link:
https://www.grandviewresearch.com/industry-analysis/gout-therapeutics-market/request/rs1
Further key findings from the study suggest:
·         Nonsteroidal Anti-inflammatory Agents (NSAIDs) accounted for the highest share of the market in 2015, which can be credited to highest penetration, higher demand due to low cost, and efficient pain relief.
·         Urate-lowering agents segment is expected to grow at the highest rate over the coming years. Expected entry of various new drugs, increasing adoption of drugs, and growing investment by key players for development of these agents are likely to drive the segment.
·         Chronic gout dominated in 2015 and is expected to maintain its dominance during the forecast period. Approval of new drugs to treat chronic gout and long-term expenditure for treatment are the key factors responsible to propel the industry.
·         NSAIDs, colchicine, and corticosteroids are majorly used to treat acute gout, and urate-lowering agents are utilized in chronic gout treatment in combination with NSAIDs or Colchicine.
·         Geographically, North America dominated the overall industry in 2015. This is attributed to higher adoption of the newer & expensive treatments and rising awareness about arthritic conditions.
·         Asia Pacific is expected to witness highest growth during the forecast period due to growing awareness and increasing healthcare expenditure. Furthermore, growing investment in the region by key players is likely to boost the regional growth.
·         Some of the key players are Takeda Pharmaceutical Company Ltd.; Novartis AG; Savient Pharmaceuticals; AstraZeneca plc; GlaxoSmithKline plc; Merck& Co. Inc.; Teijin Pharma Ltd.; and Regeneron Pharmaceuticals.
The global gout therapeutics market size was valued at USD 1.8 billion in 2015 and is projected to grow at a CAGR of around 16 % over the forecast period. This high growth is attributed to the introduction of various drugs and increasing adoption of biologics & regenerative drugs for the treatment.
Biologics such as Krystexxa, Canakinumab, and Rilonacept have been introduced in the market. Increasing adoption of these biologics because of their ability to produce powerful anti-inflammatory action is likely to drive the market during the forecast period. Furthermore, several other drugs that are in clinical trials currently are expected to be launched during the forecast period, and are likely to propel the industry.
Rising prevalence of gout across the globe due to changing lifestyle is likely to boost the industry over the coming years. Increasing alcohol consumption, high purine diet, rising obesity & kidney diseases amongst people, and consumption of certain medications such as diuretics are likely to further boost the incidence of gout.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) dominated the industry in 2015. This is attributed to the high level of penetration of drugs, availability at lower cost in comparison to drugs of other classes, and the ability to relieve pain in case of acute gout attack.
Urate-lowering agents segment is anticipated to grow with the highest rate during the forecast period. Urate-lowering agents majorly consist of xanthine oxidase inhibitor and uricosuric agents. Growing adoption of this treatment and introduction of several drugs are likely to drive the industry during the forecast period.
Have any Query? Ask our Experts:
https://www.grandviewresearch.com/inquiry/2256/ibb
Corticosteroids are generally used for patients who are intolerant to colchicine or NSAIDs. Furthermore, rebound gout attacks after withdrawal of the steroids are common and may restrain the corticosteroids segment.
The chronic gout segment dominated in 2015 and is expected to maintain its share during the forecast period. This segment encompasses urate-lowering agents such as xanthine oxidase inhibitor and uricosuric agents. Introduction of urate-lowering drugs and expected entry of pipeline drugs are likely to drive the market at the fastest rate during the forecast period.
NSAIDs, corticosteroids, and colchicine are majorly used to treat acute gout. Although the penetration of these drugs is higher, low cost as compared to urate-lowering agents and low treatment adherence are the key reasons for lower share in the market.
Grand View Research has segmented the gout therapeutics market by drug class, disease condition:
Gout Therapeutics Market Drug Class Outlook (Market Revenue in USD Million, 2014 - 2025)
·         NSAIDs
·         Corticosteroids
·         Colchicine
·         Urate-lowering agents
Gout Therapeutics Market Disease Condition Outlook (Market Revenue in USD Million, 2014 - 2025)
·         Acute Gout
·         Chronic Gout
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.



Comments

Post a Comment

Popular posts from this blog

Foot Orthotic Insoles Market 2026: What Will Be Changes In Investment Ratio With Opportunity Analysis?? |Grand View Research, Inc.

Image
The global foot orthotic insoles market size is expected to reach USD 5.5 billion by 2026 , according to a new report by Grand View Research, Inc., exhibiting a 6.3% CAGR during the forecast period. Growing incidence of diabetes and plantar fasciitis are expected to drive the market over the forecast period. Moreover, rapid urbanization and increasing disposable income are anticipated to propel growth in future. Technological advancements, spurred by ongoing investments in R&D, are expected to increase growth potential in the coming years. Moreover, rise in geriatric population, which is susceptible to orthopedic disorders, is impelling product demand globally. For instance, in 2017 as per the U.S. Census Bureau, the number of people aged 65 or older increased by 1.6 million from 2014 to 2015. In addition, increasing incidence of sports injuries and rising prevalence of osteosarcoma in the region has led to the need for various orthotics devices, which is expected to drive ...
Read more

The Future of Soft Tissue Repair….. COVID-19 & Its Impact….

The global soft tissue repair market size is expected to reach USD 10.73 billion by 2025 , expanding at a CAGR of 7.3%, according to a new report by Grand View Research, Inc. Growing number of trauma patients and orthopedic surgeries is one of the key factors expected to drive revenue growth in coming few years. With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor. Soft tissue comprises of mu...
Read more

A Look into Shapewear Industry……Deep Analysis…..

Image
The global shapewear market size is expected to reach USD 3.80 billion by 2025 registering a CAGR of 7.7%, according to a new report by Grand View Research, Inc. The introduction of various products according to the type of garments is expected to support the market growth in the years to come. Growing target population across the globe is also augmenting the market growth. Changing lifestyle incurs increased investment in fitness and related accessories, which has positively impacted the market growth. The clothing, footwear, & accessories industry is anticipated to witness checkered growth throughout 2020, as a result of the unprecedented supply chain disruptions caused by the COVID-19 outbreak worldwide. The expected decline in the global sales of clothing, footwear, & accessories is attributable to massive supply chain disruptions across significant export markets, including China and India. However, the industry is likely to recover over the forecast timeframe,...
Read more